| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8958408 | Journal of Thoracic Oncology | 2018 | 10 Pages |
Abstract
Nivolumab plus erlotinib was tolerable, with durable responses in patients with EGFR-mutant, TKI-treated NSCLC.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Scott MD, Matthew D. MD, Laura Q.M. MD, Hossein DO, Scott MD, Julie R. MD, Jonathan W. MD, David E. MD, Rosalyn A. MD, Frances A. MD, Scott A. MD, Tina C. DrPH, Xuemei MD, William J. PhD, Naiyer MD,